Compression Bandages segmentation by application reveals three dominant end‑use categories that together account for the full market. Venous insufficiency—including chronic venous disease and ulcer management—remains the largest driver, representing roughly 45 % of total revenue because of its extensive patient base and long‑term therapy protocols. Lymphedema treatment follows, contributing about 30 % of sales; the segment is expanding as awareness of post‑cancer care rises and reimbursement frameworks broaden. The remaining 25 % is captured by sports and trauma applications, where short‑term compression is employed for injury prevention, swelling control, and rehabilitation. Each application imposes distinct performance requirements on bandage construction, influencing material selection, pricing tiers, and distribution channels. Consequently, the overall market size is a weighted sum of these sub‑markets, with venous care providing the bulk of volume while sports and trauma generate higher per‑unit margins due to premium, performance‑oriented products. Regulatory compliance and clinical guideline adoption further differentiate purchasing patterns across these applications, reinforcing the proportional impact on total market valuation.